Cancer Cell-Membrane Biomimetic Boron Nitride Nanospheres for Targeted Cancer Therapy.
Cancer Cell-Membrane Biomimetic Boron Nitride Nanospheres for Targeted Cancer Therapy.
复制标题
Cancer Cell——用于癌症靶向治疗的膜仿生氮化硼纳米球
DOI：
10.2147/ijn.s266948
复制
发表时间：
2021
影响因子：
8
通讯作者：
Chen F
中科院分区：
文献类型：
--
作者：
Feng S;Ren Y;Li H;Tang Y;Yan J;Shen Z;Zhang H;Chen F
目的纳米材料为基础的药物输送系统允许有效的小分子化疗药物靶向输送到肿瘤已经彻底改变了癌症治疗。近年来，氮化硼纳米球作为一种新型的具有优异物理化学性质的纳米材料，在药物载体方面有着广阔的应用前景。然而，分散性差和缺乏肿瘤靶向严重限制了进一步的应用。本研究设计了一种肿瘤细胞膜仿生BN，用于靶向给药。方法采用物理挤压法将HeLa细胞膜包裹于BN中。将阿霉素（Dox）负载到HM-BN上作为模型药物。结果细胞膜包被使BN具有良好的生物相容性和细胞相容性。药物释放曲线显示Dox@ HM-BN响应于酸性pH，导致Dox快速释放。由于癌细胞膜的同源靶向，揭示了HeLa细胞对Dox@ HM-BN的增强的细胞摄取。CCK 8和活/死实验表明，由于细胞自身选择性摄取，Dox@ HM-BN对HeLa细胞具有更强的细胞毒性。最后，使用HeLa肿瘤模型的抗肿瘤研究表明，Dox@ HM-BN比游离Dox或Dox@ BN具有更有效的肿瘤抑制。结论HM-BN有望成为一种有效的肿瘤选择性给药载体。
Purpose Nanomaterial-based drug-delivery systems allowing for effective targeted delivery of smallmolecule chemodrugs to tumors have revolutionized cancer therapy. Recently, as novel nanomaterials with outstanding physicochemical properties, boron nitride nanospheres (BNs) have emerged as a promising candidate for drug delivery. However, poor dispersity and lack of tumor targeting severely limit further applications. In this study, cancer cell–membrane biomimetic BNs were designed for targeted anticancer drug delivery. Methods Cell membrane extracted from HeLa cells (HM) was used to encapsulate BNs by physical extrusion. Doxorubicin (Dox) was loaded onto HM-BNs as a model drug. Results The cell-membrane coating endowed the BNs with excellent dispersibility and cytocompatibility. The drug-release profile showed that the Dox@HM-BNs responded to acid pH, resulting in rapid Dox release. Enhanced cellular uptake of Dox@HM-BNs by HeLa cells was revealed because of the homologous targeting of cancer-cell membranes. CCK8 and live/dead assays showed that Dox@HM-BNs had stronger cytotoxicity against HeLa cells, due to self-selective cellular uptake. Finally, antitumor investigation using the HeLa tumor model demonstrated that Dox@HM-BNs possessed much more efficient tumor inhibition than free Dox or Dox@BNs. Conclusion These findings indicate that the newly developed HM-BNs are promising as an efficient tumor-selective drug-delivery vehicle for tumor therapy.